Abstract: Novel Hepatitis C E1 and E2 truncated polypeptides and complexes comprising these polypeptides, are disclosed. The polypeptides are C-terminally truncated to remove all or a portion of their membrane spanning domains. Hence, the polypeptides are capable of secretion when expressed recombinantly.
Abstract: Methods and compositions are provided for the production of human manganese superoxide dismutase and a protocol for enhancing efficiency of expression. The gene encoding for human manganese superoxide dismutase was isolated and inserted into a vector in conjunction with a synthetic linker which provides for enhanced efficiency in translation.
E. coli strain HB101 containing the plasmid Nco5AHSODm was deposited at the A.T.C.C. on Oct. 3, 1986 and given Accession No. 67191.
Type:
Grant
Filed:
October 14, 1986
Date of Patent:
December 4, 2001
Assignee:
Chiron Corporation
Inventors:
Robert Alexander Hallewell, Graeme Ian Bell, Guy Towns Mullenbach
Abstract: The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free, the dimeric CSF-1 consisting essentially of two monomeric human CSF-1 subunits. The present invention is further directed to pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 27, 2001
Assignee:
Chiron Corporation
Inventors:
Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird
Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
Type:
Grant
Filed:
June 11, 1999
Date of Patent:
November 27, 2001
Assignees:
Chiron Corporation, G. D. Searle & Co.
Inventors:
Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
Type:
Grant
Filed:
November 18, 1999
Date of Patent:
November 20, 2001
Assignees:
Chiron Corporation, G.D. Searle & Co.
Inventors:
Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
Abstract: Expression vectors and transfection systems providing high expression of a desired polypeptide are provided. Also provided are methods of using the expression vectors and transfection systems and mammalian cells modified by these compositions and methods.
Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.
Abstract: Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.
Abstract: Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.
Type:
Grant
Filed:
May 12, 1995
Date of Patent:
November 6, 2001
Assignee:
Chiron Corporation
Inventors:
Michael Houghton, Qui-Lim Choo, George Kuo
Abstract: Compositions and methods for expression of heterologous mammalian proteins and their secretion in the biologically active mature form using a yeast host cell as the expression system are provided. Compositions of the invention are nucleotide sequences encoding a signal peptide sequence for a yeast secreted protein, an optional leader peptide sequence for a yeast secreted protein, a native propeptide leader sequence for a mature protein of interest, and a sequence for the mature protein of interest, all operably linked to a yeast promoter. Each of these elements is associated with a processing site recognized in vivo by a yeast proteolytic enzyme. Any or all of these processing sites may be a preferred processing site that has been modified or synthetically derived for more efficient cleavage in vivo. The compositions are useful in methods for expression of heterologous mammalian proteins and their secretion in the biologically active mature form.
Abstract: Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle.
Type:
Grant
Filed:
May 2, 2000
Date of Patent:
October 23, 2001
Assignee:
Chiron Corporation
Inventors:
Derek O'Hagan, Gary Van Nest, Gary S. Ott, Manmohan Singh
Abstract: A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.
Abstract: This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositions
Abstract: An adjuvant composition, comprising a metabolizable oil and an emulsifying agent, wherein the oil and the detergent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are less than 1 micron in diameter. In preferred embodiments, the emulsifying agent is also an immunostimulating agent, such as a lipophilic muramyl peptide. Alternatively, an immunostimulating agent separate from the emulsifying agent can be used.
Type:
Grant
Filed:
April 7, 1995
Date of Patent:
October 9, 2001
Assignee:
Chiron Corporation
Inventors:
Gary Van Nest, Gary Ott, Gail Barchfeld
Abstract: The present invention discloses the amino acid and nucleic acid sequences of a new CNGC and Myosin that map to the region of the human chromosome associated with Bardet-Biedl Syndrome. Cyclic nucleotide gated channels (CNGCs) comprise a family of multimeric protein ion channels that open in response to the binding of a cyclic nucleotide to an intracellular domain. The two new proteins, CNGC-15 and Myosin IXa, are useful in the study, diagnosis and treatment of Bardet-Biedl Syndrome and Usher Syndrome. Other indications that can be treated by CNGC-15 and/or Myosin IXa polypeptides, or agonists or antagonists include hearing loss, retinis pigmentosa, obesity, hypogonadism, sterility, polydactyly, brachydactyly, syndactyly, mental retardation, renal abnormalities, hypertension, diabetes and cardiovascular abnormalities.
Compositions and methods for expressing cyclic nucleotide gated channel-15 (CNGC-15) and Myosin IXa are provided.
Type:
Grant
Filed:
October 14, 1998
Date of Patent:
October 9, 2001
Assignee:
Chiron Corporation
Inventors:
Arwen E. Adams, Choi Ying Chiu, David Duhl, Susan W. Gorman, Song Leng, Val Sheffield, Juliet Welch
Abstract: The present invention is a novel nucleic acid sequence which hybridizes to SEQ ID NO:6 or fragments thereof under stringent conditions, or fragments thereof. The invention also includes diagnostic assays, expression vectors, control sequences, antisense molecule, ribozymes, and host cells to express the polypeptide encoded by the nucleic acid sequence. The present invention also includes claims to the polypeptide sequence coded by the nucleic acid sequences.
Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.
Type:
Grant
Filed:
March 10, 1999
Date of Patent:
October 9, 2001
Assignee:
Chiron Behring GmbH & Co.
Inventors:
Bernhard Knapp, Klaus-Dieter Hungerer, Michael Bröker, Bernd-Ulrich von Specht, Horst Domdey
Abstract: Novel DNA probe sequences for detection of HIV in a sample in a solution phase sandwich hybridization assay are described. Amplified nucleic acid hybridization assays using the probes are exemplified.
Type:
Grant
Filed:
December 17, 1993
Date of Patent:
October 9, 2001
Assignee:
Chiron Corporation
Inventors:
Bruce D. Irvine, Janice A. Kolberg, Michael S. Urdea
Abstract: The present invention provides methods of treating hepatitis C infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of a hepatitis C antigen, such that an immune response is generated. Also provided are vector constructs which direct the expression of at least one portion of a hepatitis C antigen, as well as recombinant viruses which carry such vector constructs.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 2, 2001
Assignee:
Chiron Corporation
Inventors:
Douglas J. Jolly, Stephen M. W. Chang, William T. L. Lee, Kay Townsend, Joanne O'Dea
Abstract: The present application features nucleic acid, peptide and antibody compositions relating to genotypes of hepatitis C virus and methods of using such compositions for diagnostic and therapeutic purposes.
Type:
Grant
Filed:
May 16, 1995
Date of Patent:
October 2, 2001
Assignee:
Chiron Corporation
Inventors:
Tai-An Cha, Eileen Beall, Bruce Irvine, Janice Kolberg, Michael S. Urdea